Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: The LixiLan-L randomized trial

1. Aroda, V.R.
2. Rosenstock, J.
3. Wysham, C.
4. Unger, J.
5. Bellido, D.
6. González-Gálvez, G.
7. Takami, A.
8. Guo, H.
9. Niemoeller, E.
10. Souhami, E.
11. Bergenstal, R.M.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.2337/DC16-1495 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus